

# CSL™ ASX Announcement

For immediate release

19 September 2008

## UPDATE ON CSL SHARE PURCHASE PLAN

CSL Limited has today provided advice on the status of its Share Purchase Plan (*SPP*). On 25 August 2008, CSL offered eligible CSL shareholders the opportunity to participate in the SPP by subscribing for up to A\$5,000 of additional shares in CSL. The SPP forms part of the funding arrangements for CSL's proposed acquisition of Talecris Biotherapeutics.

The offer period for the SPP closed at 5.00 p.m. (Melbourne time) on Tuesday, 16 September 2008.

As at that time, applications were received from shareholders for a total of approximately A\$145 million of new CSL shares.

As previously announced, the issue price for each new CSL share under the SPP is the lower of:

- A\$36.75, being the price at which CSL shares were issued to institutional investors under the placement completed on 14 August 2008; and
- the volume weighted average price of CSL shares traded in the ordinary course on the ASX during the 15 trading day period prior to (and including) the day on which the SPP offer closed (16 September 2008) (*VWAP Price*), less a 5% discount (rounded down to the nearest cent) (the *Discounted VWAP Amount*).

The VWAP Price was A\$39.99, and the Discounted VWAP Amount is A\$37.99. Accordingly, the issue price for each new CSL share under the SPP is A\$36.75, which represents an 8% discount to the VWAP Price. 3,955,161 new CSL shares will be issued under the SPP on or about 22 September 2008.

Those new CSL shares will participate in CSL's fully-franked final dividend of 23 cents per share for FY 2007/08, payable on 10 October 2008.

For more information about CSL Limited, visit [www.csl.com.au](http://www.csl.com.au)

### For further information, please contact:

Investor Contact:

Mark Dehring

Director of Investor Relations

Phone: 61 3 9389 2818

Email: [mark.dehring@csl.com.au](mailto:mark.dehring@csl.com.au)

For personal use only